Co-Treatment of breast cancer cells with pharmacologic doses of 2-deoxy-D-glucose and metformin: Starving tumors

Oncology Reports

Volumn 37, Issue 4, 2017, Pages 2418-2424

  Wokoun, Ulrike ^a   Hellriegel, Martin ^a   Emons, Gönter ^a   Gröndker, Carsten ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

2 deoxy glycose; Breast cancer; Co Treatment; Metabolism; Metformin

Indexed keywords

DEOXYGLUCOSE; METFORMIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CELL DEATH; CELL VIABILITY; CLINICAL EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG TOLERABILITY; GLYCOLYSIS; HCC1806 CELL LINE; HUMAN; HUMAN CELL; MDA-MB-231 CELL LINE; MITOCHONDRIAL MEMBRANE POTENTIAL; PROTEIN CLEAVAGE; WESTERN BLOTTING; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DEOXYGLUCOSE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; METFORMIN; POLY(ADP-RIBOSE) POLYMERASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 85016439624     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2017.5491     Document Type: Article

References (38)

1. Warburg O: The Metabolism of Tumors. Arnold Constable, London, pp 254-270, 1930.
2. Yamamoto T, Seino Y, Fukumoto H, Koh G, Yano H, Inagaki N, Yamada Y, Inoue K, Manabe T and Imura H: Over-expression of facilitative glucose transporter genes in human cancer. Biochem Biophys Res Commun 170: 223-230, 1990.
3. Pelicano H, Martin DS, Xu RH and Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646, 2006.
4. Kaplan O, Navon G, Lyon RC, Faustino PJ, Straka EJ and Cohen JS: Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: Toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res 50: 544-551, 1990.
5. Laszlo J, Humphreys SR and Goldin A: Effects of glucose analogues (2-deoxy-D-glucose, 2-deoxy-D-galactose) on experimental tumors. J Natl Cancer Inst 24: 267-281, 1960.
6. Aft RL, Zhang FW and Gius D: Evaluation of 2-deoxy-D-glucose as a chemotherapeutic agent: Mechanism of cell death. Br J Cancer 87: 805-812, 2002.
7. Bell SE, Quinn DM, Kellett GL and Warr JR: 2-Deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Br J Cancer 78: 1464-1470, 1998.
8. Lee YJ, Galoforo SS, Berns CM, Tong WP, Kim HR and Corry PM: Glucose deprivation-induced cytotoxicity in drug resistant human breast carcinoma MCF-7/ADR cells: Role of c-myc and bcl-2 in apoptotic cell death. J Cell Sci 110: 681-686, 1997.
9. Reutter M, Emons G and Gröndker C: Starving tumors: Inhibition of glycolysis reduces viability of human endometrial and ovarian cancer cells and enhances antitumor efficacy of GnRH receptortargeted therapies. Int J Gynecol Cancer 23: 34-40, 2013.
10. Giannarelli R, Aragona M, Coppelli A and Del Prato S: Reducing insulin resistance with metformin: The evidence today. Diabetes Metab 29: 6S28-6S35, 2003.
11. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R and Zinman B; American Diabetes Association; European Association for Study of Diabetes: Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193-203, 2009.
12. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, et al: Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 40: 685-693, 2005.
13. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS and Romanyukha AA: metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9: 188-197, 2010.
14. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
15. Janjetovic K, Harhaji-Trajkovic L, Misirkic-Marjanovic M, Vucicevic L, Stevanovic D, Zogovic N, Sumarac-Dumanovic M, Micic D and Trajkovic V: In vitro and in vivo anti-melanoma action of metformin. Eur J Pharmacol 668: 373-382, 2011.
16. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD and Dennis PA: Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Cancer Prev Res 3: 1066-1076, 2010.
17. Rattan R, Graham RP, Maguire JL, Giri S and Shridhar V: Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia 13: 483-491, 2011.
18. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of AMP-Activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167-1174, 2001.
19. Camacho L, Dasgupta A and Jiralerspong S: Metformin in breast cancer-An evolving mystery. Breast Cancer Res 17: 88, 2015.
20. Emons G., Ortmann O. Becker M., Irmer G., Springer B., Laun R., Hölzel F., Schulz KD., Schally AV High affinity binding and direct antiproliferative effects of LHRH analogues in human ovarian cancer cell lines. Cancer Res 53: 5439-5446, 1993.
21. Emons G, Schröder B, Ortmann O, Westphalen S, Schulz KD and Schally AV: High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol 77: 1458-1464, 1993.
22. Irmer G, Börger C, Möller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz KD and Emons G: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 55: 817-822, 1995.
23. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, et al: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 71: 523-530, 2013.
24. FDA: Metformin: Official FDA Information, Side-Effects And Uses, 2011. https://www.fda.gov/ohrms/dockets/dailys/02/May02/053102/800471e6.pdf. Accession date: October 25, 2016.
25. Shank JJ, Yang K, Ghannam J, Cabrera L, Johnston CJ, Reynolds RK and Buckanovich RJ: Metformin targets ovarian cancer stem cells in vitro and in vivo. Gynecol Oncol 127: 390-397, 2012.
26. Zhang F and Aft RL: Chemosensitizing and cytotoxic effects of 2-deoxy-D-glucose on breast cancer cells. J Cancer Res Ther 5 (Suppl 1): S41-S43, 2009.
27. Cheong JH, Park ES, Liang J, Dennison JB, Tsavachidou D, Nguyen-Charles C, Wa Cheng K, Hall H, Zhang D, Lu Y, et al: Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther 10: 2350-2362, 2011.
28. Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, Le Marchand-Brustel Y, Giorgetti-Peraldi S, Cormont M, Bertolotto C, et al: Targeting cancer cell metabolism: The combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res 70: 2465-2475, 2010.
29. Andrzejewski S, Gravel SP, Pollak M and St-Pierre J: Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2: 12, 2014.
30. Bridges HR, Jones AJ, Pollak MN and Hirst J: Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462: 475-487, 2014.
31. Drahota Z, Palenickova E, Endlicher R, Milerova M, Brejchova J, Vosahlikova M, Svoboda P, Kazdova L, Kalous M, Cervinkova Z, et al: Biguanides inhibit complex I, II and IV of rat liver mitochondria and modify their functional properties. Physiol Res 63: 1-11, 2014.
32. El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228, 2000.
33. Owen MR, Doran E and Halestrap AP: Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348: 607-614, 2000.
34. He L and Wondisford FE: metformin action: Concentrations matter. Cell Metab 21: 159-162, 2015.
35. Brown J: Effects of 2-deoxyglucose on carbohydrate metablism: Review of the literature and studies in the rat. Metabolism 11: 1098-1112, 1962.
36. DiPaola RS, Dvorzhinski D, Thalasila A, Garikapaty V, Doram D, May M, Bray K, Mathew R, Beaudoin B, Karp C, et al: Therapeutic starvation and autophagy in prostate cancer: A new paradigm for targeting metabolism in cancer therapy. Prostate 68: 1743-1752, 2008.
37. McComb RB and Yushok WD: Metabolism of ascites tumor cells. Iv. Enzymatic reactions involved in adenosinetriphosphate degradation induced by 2-deoxyglucose. Cancer Res 24: 198-205, 1964.
38. Lalau JD and Race JM: Lactic acidosis in metformin therapy. Drugs 58 (Suppl 1): 55-82, 1999.